17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 6: | Line 6: | ||
==Surgical therapy== | ==Surgical therapy== | ||
*Patients with 17-beta hydroxysteroid dehydrogenase deficiency have [[moderate | *Patients with 17-beta hydroxysteroid dehydrogenase deficiency have [[moderate risk]] of [[germ cell tumor]]. These patients must be monitored closely, as the development of [[germ cell]] [[tumor]] requires the removal of the [[gonads]].<ref name="pmid2082839">{{cite journal| author=Melnik B, Hollmann J, Hofmann U, Yuh MS, Plewig G| title=Lipid composition of outer stratum corneum and nails in atopic and control subjects. | journal=Arch Dermatol Res | year= 1990 | volume= 282 | issue= 8 | pages= 549-51 | pmid=2082839 | doi=10.1007/BF00371952 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2082839 }} </ref> | ||
*[[Surgical]] [[treatment]] can also be used to treat [[anatomic]] changes due to the [[hormonal disorder]]. Patients with this disease may present with [[ambiguous]] or [[female genitalia]], despite most of them developing male [[gender identity]]. | *[[Surgical]] [[treatment]] can also be used to treat [[anatomic]] changes due to the [[hormonal disorder]]. Patients with this disease may present with [[ambiguous]] or [[female genitalia]], despite most of them developing male [[gender identity]]. | ||
*Some studies have suggested that early surgical treatment may improve outcomes. [[Feminizing genitoplasty]] usually requires less [[surgical interventions]] than [[masculinizing genitoplasty]]. Outcomes vary greatly in both cases. Many patients may present with risk of [[neoplasia]] associated with the [[neovagina]], while regarding the masculinizing genitoplasty's results are heavily associated with the amount of [[erectile tissue]] and degree of [[hypospadias]].<ref name="pmid2082839">{{cite journal| author=Melnik B, Hollmann J, Hofmann U, Yuh MS, Plewig G| title=Lipid composition of outer stratum corneum and nails in atopic and control subjects. | journal=Arch Dermatol Res | year= 1990 | volume= 282 | issue= 8 | pages= 549-51 | pmid=2082839 | doi=10.1007/BF00371952 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2082839 }} </ref> | *Some studies have suggested that early surgical treatment may improve outcomes. [[Feminizing]] [[genitoplasty]] usually requires less [[surgical]] [[interventions]] than [[masculinizing]] [[genitoplasty]]. Outcomes vary greatly in both cases. Many patients may present with risk of [[neoplasia]] associated with the [[neovagina]], while regarding the masculinizing genitoplasty's results are heavily associated with the amount of [[erectile tissue]] and degree of [[hypospadias]].<ref name="pmid2082839">{{cite journal| author=Melnik B, Hollmann J, Hofmann U, Yuh MS, Plewig G| title=Lipid composition of outer stratum corneum and nails in atopic and control subjects. | journal=Arch Dermatol Res | year= 1990 | volume= 282 | issue= 8 | pages= 549-51 | pmid=2082839 | doi=10.1007/BF00371952 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2082839 }} </ref> | ||
==References== | ==References== | ||
Revision as of 07:58, 20 October 2022
|
17-beta-hydroxysteroid dehydrogenase deficiency Microchapters |
|
Differentiating 17-beta-hydroxysteroid dehydrogenase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy On the Web |
|
American Roentgen Ray Society Images of 17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy |
|
FDA on 17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy |
|
CDC on 17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy |
|
17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy in the news |
|
Blogs on 17-beta-hydroxysteroid dehydrogenase deficiency surgical therapy |
|
Directions to Hospitals Treating 17-beta-hydroxysteroid dehydrogenase deficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdulkerim Yassin, M.B.B.S[2]
Overview
Surgical therapy is guided by the risk of germ cell tumor development and to allow for proper gender assignment.
Surgical therapy
- Patients with 17-beta hydroxysteroid dehydrogenase deficiency have moderate risk of germ cell tumor. These patients must be monitored closely, as the development of germ cell tumor requires the removal of the gonads.[1]
- Surgical treatment can also be used to treat anatomic changes due to the hormonal disorder. Patients with this disease may present with ambiguous or female genitalia, despite most of them developing male gender identity.
- Some studies have suggested that early surgical treatment may improve outcomes. Feminizing genitoplasty usually requires less surgical interventions than masculinizing genitoplasty. Outcomes vary greatly in both cases. Many patients may present with risk of neoplasia associated with the neovagina, while regarding the masculinizing genitoplasty's results are heavily associated with the amount of erectile tissue and degree of hypospadias.[1]
References
- ↑ 1.0 1.1 Melnik B, Hollmann J, Hofmann U, Yuh MS, Plewig G (1990). "Lipid composition of outer stratum corneum and nails in atopic and control subjects". Arch Dermatol Res. 282 (8): 549–51. doi:10.1007/BF00371952. PMID 2082839.